Deadly Strain Spreads — One Shot Races In

A Singapore-based lab is racing to build the world’s “most promising” Ebola shot for a deadly new outbreak, using technology first proven by an American company and now backed by global health agencies.

Story Snapshot

World Health Organization experts picked a single-dose rVSV Bundibugyo Ebola vaccine as the top candidate for the current outbreak.
Singapore’s Hilleman Laboratories will develop and produce doses for human trials, using know-how from Merck’s proven Ebola vaccine.
The Bundibugyo strain has no licensed vaccine or treatment today, while cases and deaths climb in the Democratic Republic of the Congo and Uganda.
President Trump’s America stays at low direct risk for now, but the outbreak tests global biosecurity and vaccine supply chains that protect U.S. citizens.

WHO backs single-dose Bundibugyo Ebola shot as top candidate

Experts brought together by the World Health Organization reviewed all available Bundibugyo Ebola vaccine options earlier this year and made a clear call. They judged a one-dose recombinant vesicular stomatitis virus Bundibugyo vaccine, known as rVSV Bundibugyo, as the “most promising” candidate to prevent disease from this strain. They warned it will still take about seven to nine months of work before this shot is ready for full clinical trials in humans. That timeline matters with thousands of infections already reported.

The same expert panel noted another vaccine, called ChAdOx1 Bundibugyo and developed by Oxford University and the Serum Institute of India, could reach testing faster, in about two to three months. But they still ranked the single-dose rVSV Bundibugyo candidate higher overall because of its platform’s strong past record and preclinical data. This shows how global health officials are willing to move quickly when a tool looks most likely to work, even before full human data is in place.

Singapore’s Hilleman Labs steps in with Merck’s rVSV know-how

The Coalition for Epidemic Preparedness Innovations, which helps fund vaccines for dangerous outbreaks, announced a deal with Hilleman Laboratories in Singapore to push the rVSV Bundibugyo shot forward. CEPI is putting up to $8.5 million on the table so Hilleman can refine the manufacturing process and produce clinical trial doses at its vaccine facility. Hilleman will start from material first made by the International AIDS Vaccine Initiative, then carry it through the steps needed for human testing.

Hilleman Laboratories is a joint venture between American drug maker Merck (also known as MSD) and the British charity Wellcome Trust. Merck created and produces Ervebo, the approved rVSV-based vaccine against the Zaire strain of Ebola, and will serve as a technical adviser on this new Bundibugyo project. That means the same U.S.-linked technology that proved itself in past Ebola emergencies is being used again, this time through a Singapore group aiming to deliver a single-dose shot for this new strain.

Why Bundibugyo Ebola demands a strain-specific vaccine

Bundibugyo virus is a rarer Ebola strain, but it is driving a major health crisis in the Democratic Republic of the Congo and Uganda. World Health Organization reports say there is no licensed vaccine or specific treatment for Bundibugyo virus disease, even though early supportive care can save lives. As of early June, over 500 confirmed cases and dozens of deaths were already logged in Congo, with more cases and deaths in Uganda. Later counts from European disease trackers climbed into the thousands.

Existing Ebola vaccines are built for the Zaire strain and are not approved for Bundibugyo infections. Data from past work show those Zaire vaccines give only partial protection, about 75 percent, against other Ebola species such as Bundibugyo. Doctors Without Borders and other groups say response today still relies on basic tools: fast case finding, isolation, contact tracing, infection control, and safe burials. That is why global agencies are pushing hard for a Bundibugyo-specific vaccine and calling the rVSV candidate their top shot in the pipeline.

Proven rVSV platform, fast timelines, and what it means for Americans

The rVSV platform is not new or untested. It is based on a weakened vesicular stomatitis virus that has been changed to display an Ebola glycoprotein on its surface. Studies in animals and later human trials showed rVSV-based vaccines can give strong protection with a single injection, and this approach led to the approved Ervebo shot for Zaire Ebola. For Bundibugyo virus, early animal work with the rVSVΔG/BDBV-GP construct showed a survival benefit in non-human primates in a 2023 proof-of-concept study. That evidence helped convince World Health Organization experts to back it as the leading candidate.

🇨🇩 BREAKING: DRC Ebola outbreak hits 3,075 cases, 1,354 deaths.

⚡ Fastest-growing outbreak in history
⚡ Rare Bundibugyo strain — no cure
⚡ WHO declares global health emergency

👇 Should the world respond faster?#DRC #Ebola #GlobalHealth #WHO #BreakingNews pic.twitter.com/oW41S1fvQW

— Septentria News (@SeptentriaNews) July 27, 2026

The Centers for Disease Control and Prevention says no Ebola cases from this Bundibugyo outbreak have been confirmed in the United States, and overall risk to the American public remains low. But the scale of the African outbreak and the lack of approved countermeasures highlight how fragile global health systems can be. For conservatives who care about strong borders, honest spending, and real national security, this story is a reminder that dangerous viruses do not respect borders, and America’s safety depends on smart investment in targeted, effective vaccines rather than blank-check globalism or wasteful bureaucracy.